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Abstract
Background:  Peripheral nerve injury leads to a persistent neuropathic pain state in which
innocuous stimulation elicits pain behavior (tactile allodynia), but the underlying mechanisms have
remained largely unknown. We have previously shown that spinal nerve injury induces the
activation of cytosolic phospholipase A2 (cPLA2) in injured dorsal root ganglion (DRG) neurons that
contribute to tactile allodynia. However, little is known about the signaling pathway that activates
cPLA2 after nerve injury. In the present study, we sought to determine the mechanisms underlying
cPLA2 activation in injured DRG neurons in an animal model of neuropathic pain, focusing on
mitogen-activated protein kinases (MAPKs) and Ca2+/calmodulin-dependent protein kinase II
(CaMKII).
Results: Pharmacological inhibition of either p38 or extracellular signal-regulated kinase (ERK) in
the injured DRG, which led to suppression of the development of tactile allodynia, did not affect
cPLA2 phosphorylation and translocation after nerve injury. By contrast, a CaMKII inhibitor
prevented the development and expression of nerve injury-induced tactile allodynia and reduced
both the level of cPLA2 phosphorylation and the number of DRG neurons showing translocated
cPLA2 in response to nerve injury. Applying ATP to cultured DRG neurons increased the level of
both phosphorylated cPLA2 and CaMKII in the vicinity of the plasma membrane and caused physical
association of these two proteins. In addition, ATP-stimulated cPLA2 and CaMKII phosphorylation
were inhibited by both a selective P2X3R/P2X2+3R antagonist and a nonselective voltage-dependent
Ca2+ channel (VDCC) blocker.
Conclusion: These results suggest that CaMKII, but not MAPKs, has an important role in cPLA2
activation following peripheral nerve injury, probably through P2X3R/P2X2+3R and VDCCs in
primary afferent neurons.
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Background
Peripheral nerve injury leads to a persistent neuropathic
pain state in which innocuous stimulation elicits pain
behavior (tactile allodynia). Effective therapy for this pain
is lacking, and the underlying mechanisms have remained
largely unknown. We have previously shown that spinal
nerve injury induces the activation of cytosolic phosphol-
ipase A2 (cPLA2), a Ca2+-dependent subclass of the PLA2
family [1], in DRG neurons, and that inhibiting cPLA2
suppresses nerve injury-induced tactile allodynia, reveal-
ing a crucial role for this enzyme in neuropathic pain [2].
Activated cPLA2 hydrolyzes the sn-2 position of glycero-
phospholipids to release arachidonic acid and lysophos-
pholipid, and subsequently generates lipid mediators
such as prostaglandins, leukotrienes, platelet-activating
factor and lysophosphatidic acid. These mediators have
been reported to cause sensitization of primary afferent
neurons [3-5] and to produce allodynic behaviors [6-9].
Activation of P2X3 and P2X2+3 receptors (P2X3R/P2X2+3R),
ionotropic ATP receptor subtypes, is involved in nerve
injury-induced cPLA2  activation in DRG neurons [2];
however, the mechanism underlying cPLA2 activation via
P2X3R/P2X2+3R remains to be elucidated.
The activation of cPLA2 is regulated by phosphorylation of
serine residues in addition to a rise in intracellular Ca2+
concentration [10]. The catalytic domain of cPLA2 con-
tains several phosphorylation sites, Ser505, Ser515 and
Ser727, which have been reported to be phosphorylated
by mitogen-activated protein kinases (MAPKs) [11-13],
Ca2+/calmodulin-dependent protein kinase II (CaMKII)
[14] and MAPK-interacting kinase 1 (MNK1) or a closely
related isoform [15], respectively. Among these serine res-
idues, phosphorylation of cPLA2 at Ser505 and Ser727 has
been shown to be important for agonist-induced arachi-
donic acid release in mammalian cell models [11,15-17].
It is possible that the phosphorylation of these three ser-
ine residues may be interactive, because MNK1 is acti-
vated by MAPKs such as p38 and extracellular signal-
regulated kinase (ERK) [18], and CaMKII modulates ERK
activation [19,20]. Indeed, it has been recently shown that
phosphorylation on Ser505 by ERK is dependent upon
Ser515 phosphorylation via the activation of CaMKII in
vascular smooth muscle cells [21].
Among protein kinases involved in cPLA2  activation
described above, MAPKs and CaMKII are expressed in
DRG neurons and have important roles in pain signaling.
Nerve injury induces an increase in p38 and ERK phos-
phorylation in DRG neurons and injection of these inhib-
itors attenuates nerve injury-induced tactile allodynia
[22], strongly suggesting that MAPK activation in primary
afferent neurons participates in neuropathic pain after
nerve injury. CaMKII, which is especially abundant in the
nervous system, has been implicated in various neuronal
functions, such as the synthesis and release of neurotrans-
mitter, modulation of ion channels and receptors, gene
expression and synaptic plasticity. Recently, it was
reported that CaMKII is localized in small- and medium-
diameter DRG neurons that are known to transmit nocic-
eptive signals [23,24]. Intraplantar injection of complete
Freund's adjuvant (CFA), a model of inflammatory pain,
increases the expression of CaMKII in sensory neurons
[24], and CaMKII activation regulates the activity of tran-
sient receptor potential vanilloid type 1 (TRPV1) [25,26].
Thus, it raises the possibility that peripheral nerve injury
may induce the activation of cPLA2 via the phosphoryla-
tion of MAPKs and CaMKII in primary afferent neurons,
but their roles remain to be determined.
While cPLA2 is distributed throughout the cytoplasm in
the normal condition, in response to a variety of extracel-
lular stimuli, an increase in intracellular Ca2+ concentra-
tion promotes binding of Ca2+ to the C2 domain and then
allows cPLA2  to translocate to the perinuclear region,
including the nuclear envelope, Golgi apparatus and
endoplasmic reticulum in non-neuronal cells [27-31]. By
contrast, our previous study showed that phosphorylated
cPLA2 translocates to the plasma membranes of injured
DRG neurons. Therefore, the translocation of cPLA2 in
DRG neurons seems to be unique, but the mechanism of
cPLA2  translocation remains unknown. In the present
study, we investigated the involvement of MAPKs and
CaMKII in cPLA2 phosphorylation and translocation in
DRG neurons following peripheral nerve injury using
pharmacological and molecular approaches.
Results
Inhibition of neither p38 nor ERK prevents the activation 
of cPLA2 after nerve injury
An injury to the L5 nerve caused an increase in the phos-
phorylation of p38 mainly in small-diameter DRG neu-
rons (data not shown), as previously demonstrated [22].
Nerve injury also induced an increase in ERK phosphor-
ylation in satellite glial cells, and to a lesser extent, in
large-diameter DRG neurons (Figure 1B). To examine the
involvement of ERK and p38 in cPLA2 activation in DRG
neurons, we tested the effects of inhibitors for MAPK
kinase (MEK, a kinase upstream of ERK) and p38 that
were administered through a catheter whose tip was posi-
tioned near the L5 DRG [2]. Vehicle-treated rats with an
L5 nerve injury displayed a marked decrease in paw with-
drawal threshold after nerve injury (Figure 1A and Figure
2A). By contrast, U0126, a selective inhibitor of MEK, and
SB203580, a potent inhibitor of p38, significantly sup-
pressed the development of tactile allodynia, as previ-
ously demonstrated [22] (U0126, p < 0.001; SB203580, p
< 0.001) (Figure 1A and Figure 2A). Whereas p38 phos-
phorylation in DRG neurons was not inhibited by
SB203580 (data not shown), because SB203580 binds toMolecular Pain 2009, 5:22 http://www.molecularpain.com/content/5/1/22
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the ATP pocket in p38 to inhibit its kinase activity [32],
ERK phosphorylation was suppressed by U0126 (Figure
1B). However, on day 7, the levels of phosphorylated
cPLA2 (p-cPLA2) in the ipsilateral DRGs of U0126- and
SB203580-treated rats were not changed compared with
that in vehicle-treated rats. (Figure 1B and Figure 1C, Fig-
ure 2B and Figure 2C). Similar results were obtained in
immunohistochemical analyses using the ipsilateral L5
DRG that was removed 45–60 min after injection of these
inhibitors (data not shown). These results indicate that
p38 and ERK are not involved in nerve injury-induced
cPLA2 activation in DRG neurons.
Peripheral nerve injury induces CaMKII activation in 
primary afferent neurons
To examine whether spinal nerve injury induces the acti-
vation of CaMKII in DRG neurons, we performed immu-
nohistochemical analysis using the DRGs of nerve-injured
rats. We found that L5 nerve injury caused an increase in
the level of phosphorylated CaMKII-immunoreactivity (p-
A MEK inhibitor U0126 does not prevent cPLA2 activation after nerve injury Figure 1
A MEK inhibitor U0126 does not prevent cPLA2 activation after nerve injury. (A) Effect of U0126 on the develop-
ment of nerve injury-induced tactile allodynia. Results are means ± SEM of the paw withdrawal thresholds on the ipsilateral 
(ipsi) and contralateral (contra) sides. **p < 0.01, ***p < 0.001 compared with the threshold on day 0. ###p < 0.001 compared 
with the threshold of the vehicle-treated group. (B, C) Immunohistochemical (B) and western blot (C) analyses of p-ERK and p-
cPLA2 proteins in the ipsilateral L5 DRG of vehicle- and U0126-treated rats 7 days after nerve injury. Scale bar, 50 μm.
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CaMKII-IR) in the ipsilateral L5 DRG (Figure 3A). Accu-
mulated p-CaMKII-IR was not observed in the contralat-
eral DRG (Figure 3A). At the subcellular level, p-CaMKII-
IR in damaged DRG neurons was accumulated at the
edges of the area immunostained with the neuronal
marker microtubule-associated protein 2 (MAP2) (Figure
3B).
A CaMKII inhibitor suppresses nerve injury-induced cPLA2 
activation
Recent evidence has indicated that CaMKII plays an
important role in the phosphorylation of cPLA2 in vitro
[14,21], suggesting a role for CaMKII in cPLA2 phosphor-
ylation in injured DRG neurons. To investigate this
hypothesis, we examined co-localization of phosphor-
ylated cPLA2 and CaMKII in DRG neurons. Since it is dif-
ficult to perform double-immunolabeling of tissue with
p-cPLA2  and p-CaMKII antibodies, because they were
raised in the same host species (rabbit), we used two adja-
cent DRG sections and singly immunostained one section
with each antibody. We observed DRG neurons that were
positive for both p-cPLA2 and p-CaMKII in the injured
DRG (indicated by arrowheads, Figure 4A). To further test
whether the inhibition of CaMKII activation affects nerve
injury-induced cPLA2 activation, we injected a CaMKII
inhibitor, KN-93, and a negative control for KN-93, KN-
92, into nerve-injured rats. We found that the levels of
both p-CaMKII and p-cPLA2 in the ipsilateral DRG of KN-
93-treated rats were much lower than those in KN-92-
treated rats (Figure 4B and Figure 4C), and administration
of KN-93 markedly reduced the number of DRG neurons
showing translocated p-cPLA2 in response to nerve injury
(p < 0.001) on day 7 (Figure 4D) compared with KN-92
(Figure 4D) or vehicle administration (n  = 2, 38.3 ±
0.3%). These results suggest that CaMKII is involved in
cPLA2 phosphorylation and translocation in DRG neu-
rons caused by nerve injury. In addition, KN-93 signifi-
cantly suppressed the development of tactile allodynia
(day 3: p < 0.01, day 7: p < 0.001) (Figure 4E) and a single
administration of KN-93 near the DRG 7 days after nerve
injury also significantly suppressed the expression of tac-
tile allodynia (p < 0.001) (Figure 4F). No alteration in
A p38 inhibitor SB203580 does not prevent cPLA2 activation after nerve injury Figure 2
A p38 inhibitor SB203580 does not prevent cPLA2 activation after nerve injury. (A) Effect of SB203580 on the 
development of nerve injury-induced tactile allodynia. Results are means ± SEM of the paw withdrawal thresholds on the ipsi-
lateral (ipsi) and contralateral (contra) sides. ***p < 0.001 compared with the threshold on day 0. ###p < 0.001 compared with 
the threshold of the vehicle-treated group. (B, C) Immunohistochemical (B) and western blot (C) analyses of p-cPLA2 protein 
in the ipsilateral L5 DRG of vehicle- and SB203580-treated rats 7 days after nerve injury. Scale bar, 50 μm.
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motor behavior after KN-93 treatment was observed (data
not shown). Taken together, these results indicate that
inhibiting CaMKII activation prevents the development
and expression of nerve injury-induced tactile allodynia.
ATP receptor-dependent activation of CaMKII in cultured 
primary sensory neurons
cPLA2 is activated via P2X3R/P2X2+3R in DRG neurons
after nerve injury [2]. To examine whether CaMKII is also
activated by these receptors, we applied ATP to cultured
DRG neurons and found that the level of p-CaMKII-IR
was increased in the vicinity of the plasma membranes of
DRG neurons, similar to the translocation of p-cPLA2 after
applying ATP (Figure 5A). Next, to investigate the physical
association between p-CaMKII and p-cPLA2, we per-
formed immunoprecipitation experiments and found
that p-CaMKII was coimmunoprecipitated with p-cPLA2
in DRG neurons after the application of ATP (Figure 5B).
Applying α,β-methylene ATP (αβmeATP), an agonist of
P2X1- and P2X3-containing P2XRs, also increased p-cPLA2
and p-CaMKII levels (Figure 6A). When DRG neurons
were pre-treated with KN-93 or A-317491, a potent and
selective antagonist of P2X3R/P2X2+3R, prior to applying
ATP, the ATP-induced phosphorylation of cPLA2  and
CaMKII were significantly inhibited (Figure 6B). We also
examined the contribution of voltage-dependent Ca2+
channels (VDCCs) to CaMKII activation, because Ca2+
influx via VDCCs has been reported to also be involved in
CaMKII activation in neuronal cells [33]. The increases in
the levels of p-cPLA2 and p-CaMKII induced by αβmeATP
were abolished by cadmium, a nonselective blocker of
VDCCs (Figure 6C). Furthermore, applying BayK8644, an
agonist for VDCCs, to primary DRG neurons increased the
level of p-CaMKII-IR in the vicinity of the plasma mem-
branes of DRG neurons and caused the translocation of p-
cPLA2  (Figure 6D). These results indicate that P2X3R/
P2X2+3R and VDCCs have important roles in cPLA2 and
CaMKII activation, and that p-cPLA2 is translocated to the
plasma membranes of DRG neurons as a result of its inter-
action with p-CaMKII.
Discussion
In the present study, we demonstrated for the first time
that activation of CaMKII in DRG neurons is important
for cPLA2 phosphorylation and translocation as well as
the development and maintenance of neuropathic pain
after peripheral nerve injury.
p38 and ERK have been shown to be involved in the phos-
phorylation of cPLA2 in non-neuronal cells [11-13] and to
be activated in DRG neurons after spinal nerve injury [22].
Although p38 and MEK inhibitors administered near the
injured DRG prevented the development of tactile allody-
nia, these did not affect the activation of cPLA2. It is thus
conceivable that p38 and ERK in DRG neurons participate
in the development of tactile allodynia through an inde-
pendent pathway or downstream of the cPLA2-mediated
signaling pathway. In particular, ERK and cPLA2 are acti-
vated in different types of cells in the injured DRG: ERK
phosphorylation was seen predominantly in satellite glial
cells, while activation of cPLA2 is observed mainly in
medium-to-large-diameter DRG neurons [2], which sup-
ports our hypothesis. Alternatively, it is also possible that
cPLA2-mediated lipid mediators, such as prostaglandins,
platelet-activating factor and lysophosphatidic acid,
which have been reported to produce tactile allodynia [6-
9], may affect the excitation of DRG neurons via MAPK
activation in primary afferent neurons. Studies in our lab-
oratory determining cPLA2-mediated products and their
roles in neuropathic pain are currently underway.
Recently, it was reported that cPLA2 is phosphorylated by
CaMKII in vitro [14,21]. CaMKII is preferentially localized
in pain-processing regions in the nervous system, such as
the superficial laminae of the dorsal horn in the spinal
cord and dorsal root ganglion [23,24]. CaMKII activity is
significantly increased in the spinal cord after injection of
capsaicin and formalin [34,35] and CFA-induced pain
behaviors and increase of CaMKII phosphorylation in the
spinal dorsal horn are reduced by KN-93 [36]. Further-
more, intrathecal injection of KN-93 attenuates the devel-
opment of thermal hyperalgesia and mechanical
allodynia following chronic constriction injury (CCI)
[37]. These findings suggest that CaMKII expressed in the
CaMKII is activated in DRG neurons after nerve injury Figure 3
CaMKII is activated in DRG neurons after nerve 
injury. (A) Immunohistochemical analysis of p-CaMKII pro-
tein in the L5 DRG 7 days after nerve injury. (B) Double 
immunofluorescence labeling of p-CaMKII with MAP2, a 
marker of neurons, in the ipsilateral L5 DRG 7 days after 
nerve injury. Scale bar, 50 μm.
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Figure 4 (see legend on next page)
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spinal cord contributes to chronic inflammatory and neu-
ropathic pain as well as acute pain. By contrast, in DRG
neurons, the phosphorylation of CaMKII has an impor-
tant role in nerve growth factor-induced sensitization of
TRPV1 [25] and modulation of the agonist binding to
TRPV1 [26]. CaMKII expression in sensory neurons has
been shown to be increased during chronic inflammation
pain [24], but there have been no reports investigating the
role of CaMKII in DRG neurons in neuropathic pain. In
our immunohistochemical analyses, the level of CaMKII
phosphorylation was increased in the ipsilateral DRG
neurons after nerve injury. We also found that DRG neu-
rons showing translocation of both phosphorylated cPLA2
and CaMKII to the plasma membrane were observed in
the injured DRG. Importantly, pharmacological blockade
of CaMKII prevented cPLA2 phosphorylation and translo-
cation as well as tactile allodynia following peripheral
nerve injury. These results suggest that the phosphoryla-
tion and translocation of cPLA2 to the plasma membrane
via an interaction with activated CaMKII is a key event in
the development of nerve injury-induced tactile allody-
nia. Our present behavioral study also reveals that KN-93
is effective in treating existing tactile allodynia, which is
consistent with the behavioral analysis using a cPLA2
inhibitor [2]. Considering a previous result showing that
KN-93 administered near the spinal cord 7 days after CCI
produces no significant effect on existing tactile allodynia
[37], the role of CaMKII in the maintenance phase of neu-
ropathic pain may be predominant in the DRG rather
than in the spinal cord.
Applying ATP caused an increase in the levels of both
phosphorylated cPLA2 and CaMKII in the vicinity of the
plasma membrane, and physical association of these two
proteins in primary cultured DRG neurons. ATP receptor
agonist-dependent phosphorylation of cPLA2 and CaMKII
were inhibited either by the selective P2X3R/P2X2+3R
antagonist A-317491 or by the nonselective VDCC
blocker cadmium. Because the ATP-evoked current is not
blocked by cadmium [38,39], our results suggest that Ca2+
influx via the activation of P2X3R/P2X2+3R may not be
enough to activate CaMKII and that VDCC activation
(presumably resulting from a depolarization of DRG neu-
rons by stimulating P2X3R/P2X2+3R) may contribute to
CaMKII activation in DRG neurons. Activation of CaMKII
and cPLA2 in A23187-stimulated DRG neurons supports
this notion. Subsequently, activated CaMKII would phos-
phorylate cPLA2 and be translocated to the plasma mem-
brane by interacting physically with activated cPLA2. To
date, there have been many studies investigating CaMKII
translocation and its roles in synaptic transmission and
plasticity in the central nervous system. In hippocampal
neurons, CaMKII is activated by Ca2+  influx through
NMDA receptors and then translocated to postsynaptic
density (PSD) [40] in parallel with sustained CaMKII
activity owing to an interaction with the NMDA receptor
subunit NR2B [41]. Activated CaMKII subsequently phos-
phorylates many PSD proteins, including AMPA recep-
tors, and binds to NMDA receptor subunits, resulting in
induction of long-term potentiation [42,43]. In relation
to pain, a previous study has reported that inhibition of
CaMKII activity blocks translocation of AMPA receptor
subunits to the plasma membrane of spinal cord neurons
after capsaicin stimulation [44]. Although there have been
few reports investigating the translocation of CaMKII in
the peripheral nervous system, a recent study demon-
strated that CaMKII activated by electric stimulation of the
sciatic nerve is implicated in the trafficking of P2X3R
toward the plasma membranes of DRG neurons [45].
Given the present data showing that cPLA2 and CaMKII
are activated via stimulation of P2X3R/P2X2+3R in DRG
neurons, this work indicates that P2X3R/P2X2+3R-depend-
ent activation of cPLA2 and CaMKII is enhanced under
pathological conditions, such as neuropathic pain.
Conclusion
The present study demonstrated that CaMKII, but not
MAPKs, has an important role in cPLA2-dependent tactile
allodynia via the regulation of phosphorylation and trans-
location of cPLA2, both of which are mediated by P2X3R/
P2X2+3R and voltage-dependent Ca2+ channels in primary
afferent neurons following peripheral nerve injury. Our
A CaMKII inhibitor KN-93 suppresses tactile allodynia and cPLA2 activation Figure 4 (see previous page)
A CaMKII inhibitor KN-93 suppresses tactile allodynia and cPLA2 activation. (A-C) Immunohistochemical (A, B) and 
western blot (C) analyses of p-CaMKII and p-cPLA2 proteins in the ipsilateral L5 DRG of KN-92- and KN-93-treated rats 7 
days after nerve injury. Arrowheads show DRG neurons positive for both p-CaMKII and p-cPLA2. Scale bar, 50 μm. (D) The 
number of p-cPLA2-translocated neurons in the ipsilateral L5 DRG 7 days after nerve injury. About 1000 neurons profiles were 
counted in twenty randomly chosen sections from six rats in each group. Results are percentages (means ± SEM) of p-cPLA2-
translocated neurons (p-cPLA2 neurons) relative to the total number of neurons. ***p < 0.001 compared with the KN-92-
treated group. (E) Effect of KN-93 on the development of nerve injury-induced tactile allodynia. Results are means ± SEM of 
the paw withdrawal thresholds on the ipsilateral (ipsi) and contralateral (contra) sides. ***p < 0.001 compared with the thresh-
old on day 0. ##p < 0.01, ###p < 0.001 compared with the threshold of the KN-92-treated group. (F) Effect of a single admin-
istration of KN-93 on the decrease in paw withdrawal threshold (mean ± SEM) 7 days after nerve injury. ***p < 0.001 
compared with pre-injury baseline (Pre). ###p < 0.001 compared with the threshold on day 7.Molecular Pain 2009, 5:22 http://www.molecularpain.com/content/5/1/22
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results provide important evidence to help us to under-
stand the mechanism underlying neuropathic pain mod-
ulated by cPLA2  and the translocation of cPLA2  and
CaMKII in DRG neurons under pathophysiological condi-
tions.
Methods
Animals
Male Wistar rats (250–300 g) were used. Animals were
housed at a temperature of 22 ± 1°C with a 12-h light-
dark cycle (light on 8:30 to 20:30), and fed food and water
ad libitum. All of the animals used in the present study
were obtained, housed, cared for and used in accordance
with the guidelines of Kyushu University.
Neuropathic pain model
We used the spinal nerve injury model [46] with some
modifications [47]: in male Wistar rats a unilateral L5 spi-
nal nerve was tightly ligated and cut just distal to the liga-
ture. The mechanical allodynia was assessed by using
calibrated von Frey filaments (0.4–15.1 g, Stoelting,
Wood Dale, Illinois, USA) and the paw withdrawal
threshold was determined as described previously [47].
Drug treatment
Rats were implanted with catheters for intrathecal injec-
tion according to the method described previously. Under
isoflurane anesthesia, a sterile 32 gauge intrathecal cathe-
ter (ReCathCo, Allison Park, Pennsylvannia, USA) was
inserted through the atlanto-occipital membrane and to
the L4 or L5 DRG and externalized through the skin [2].
After the experiments, we confirmed that the tip of the
catheter was positioned near the L5 DRG. Rats were
injected intrathecally with each drug using a 25 μl Hamil-
ton syringe with a 30-gauge needle once a day from day 0
(just before the nerve injury) to day 6. The drugs used in
this study are listed below: SB203580 (30 nmol/10 μl,
Calbiochem, San Diego, California, USA), U0126 (10
nmol/10 μl, Promega, Madison, Wisconsin, USA), KN-92
(10 nmol/10 μl, Calbiochem) and KN-93 (10 nmol/10 μl,
Calbiochem). The paw withdrawal threshold was tested
21–24 hr after the injection of each drug at 1, 3, 7 days
post-injury. After the test on day 7, to examine the level of
p-cPLA2 in injured DRG neurons in vehicle- and inhibitor-
treated groups using immunohistochemistry and western
blotting, the L5 DRG ipsilateral to the nerve injury was
removed. For the experiment in which the effect of a sin-
gle administration of KN-93 on the established allodynia
was examined on day 7 after nerve injury, behavioral test
was performed immediately before and after the injection
of KN-93 (10 nmol/10 μl).
Immunohistochemistry
Rats were deeply anesthetized by pentobarbital (100 mg/
kg, i.p.) and perfused transcardially with 4% paraformal-
cPLA2 and CaMKII are activated in the plasma membrane  after applying ATP Figure 5
cPLA2 and CaMKII are activated in the plasma mem-
brane after applying ATP. (A) Increase in the levels of p-
cPLA2 and p-CaMKII immunofluorescence and translocation 
of these proteins to the plasma membrane in neurons 5 min 
after the application of 10 μM ATP compared with controls. 
Similar results were observed in each of three experiments. 
Scale bar, 20 μm. (B) The association between p-cPLA2 and 
p-CaMKII after application of 10 μM ATP. Protein samples 
were subjected to immunoprecipitation with the anti-p-
cPLA2 antibody, and isolated complex was separated by elec-
trophoresis and immunoblotted with anti-p-cPLA2 and anti-p-
CaMKII antibodies.
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cPLA2 and CaMKII are activated via stimulation of P2X3 and P2X2+3 receptors in primary DRG neurons Figure 6
cPLA2 and CaMKII are activated via stimulation of P2X3 and P2X2+3 receptors in primary DRG neurons. (A-C) 
Western blot analyses of p-cPLA2 and p-CaMKII proteins after applying ATP or α,β-methylene ATP (αβmeATP) to rat primary 
DRG neurons. The primary DRG culture was incubated with ATP or αβmeATP. KN-92, KN-93, A-317491 or cadmium was 
added to the neurons 10 min before the application of ATP or αβmeATP. The total cPLA2 and CaMKII proteins loaded on each 
lane were also detected as loading controls. The bar graphs show the relative values of p-cPLA2 and p-CaMKII proteins induc-
tion with respect to controls, after normalizing for the cPLA2 and CaMKII protein levels, respectively. *p < 0.05 compared with 
the control group. #p < 0.05 compared with the ATP- or αβmeATP-stimulated group. (D) Increase in the levels of p-cPLA2 and 
p-CaMKII immunofluorescence and translocation of these proteins to the plasma membrane in neurons 5 min after the applica-
tion of 10 μM BayK8644 compared with controls. Scale bar, 20 μm.
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dehyde. DRG sections were removed, postfixed with the
same fixative, and placed in 30% sucrose solution for 24
hr at 4°C. The DRG sections (15 μm) were incubated in a
blocking solution [3% normal goat serum/0.3% Triton X-
100/phosphate-buffered saline (PBS) (-) ] and then with
anti-phospho-ERK (anti-p-ERK) antibody (1:500, Cell
Signaling, Beverly, Massachusetts, USA), anti-phospho-
cPLA2  (anti-p-cPLA2) antibody (1:200, Abcam, Cam-
bridge, Massachusetts, USA) or anti-phospho-CaMKII
(anti-p-CaMKII) antibody (1:500, Promega). Identifica-
tion of the type of p-CaMKII-translocated cells was per-
formed with MAP2, a marker of neurons (1:1000,
Chemicon, Temecula, California, USA). Following incu-
bation, the DRG sections were incubated with anti-rabbit
immunoglobulin G (IgG)-conjugated Alexa Fluor 488 or
anti-mouse IgG-conjugated Alexa Fluor 546 (1:1000,
Molecular Probes, Eugene, Oregon, USA). The sections
were then analyzed by a confocal microscope (LSM510,
Zeiss, Oberkochen, Germany). The number of p-cPLA2-IR
DRG neurons with translocation was counted in the L5
DRG ipsilateral to the nerve injury. The proportion of the
p-cPLA2-translocated neurons to the total number of DRG
neurons was determined in twenty randomly chosen sec-
tions from six rats in KN-92- and KN-93-treated groups.
Western blotting
Rats were deeply anesthetized by pentobarbital (100 mg/
kg, i.p.) and the L5 DRG ipsilateral to the nerve injury was
quickly removed. The tissue was then homogenized in
homogenization buffer (20 mM Tris-Hcl pH 7.4, 2 mM
EDTA, 0.5 mM EGTA, 0.32 M sucrose, protease and phos-
phatase inhibitors cocktails) for 10 s on ice and centri-
fuged at 1000 × g for 5 min at 4°C to remove cell debris.
The supernatant was transferred to a new tube, mixed with
Laemmli sample buffer (125 mM Tris-HCl pH 7.4, 20%
glycerol, 4% (w/v) sodium dodecyl sulfate (SDS), 0.025%
(w/v) bromophenol blue and 5% 2-mercaptoethanol),
and boiled at 95°C for 5 min. All samples were subjected
to BCA assay to adjust the loading protein amount before
adding the Laemmli sample buffer. The samples were sub-
jected to a 7.5% polyacrylamide gel (BioRad, Hercules,
CA, USA), and the proteins were transferred electropho-
retically to polyvinylidene difluoride membranes. After
blocking, the membranes were incubated with anti-p-
cPLA2 antibody (1:1000, Cell Signaling), anti-cPLA2 anti-
body (1:1000, Cell Signaling) overnight at 4°C and then
were incubated with horseradish peroxidase-conjugated
anti-rabbit IgG antibody (1:1000, Amersham Biosciences,
Buckinghamshire, UK). The blots were detected using a
chemiluminescence method (ECL system; Amersham Bio-
sciences).
Culture of rat primary DRG neurons
The lumber DRGs (L1-6 segments) were removed from
male Wistar rats and were treated in Dulbecco's modified
eagle medium with 20 U/ml papain and 2 mg/ml colla-
genase type II for 1 hr at 37°C. At the end of this treatment
the enzyme solution was removed and the DRGs were
mechanically dissociated by trituration through a Pasteur
pipette in Dulbecco's modified eagle medium. They were
suspended in F-12 Nutrient Mixture liquid supplemented
with 10% horse serum, 2 mM glutamine, 100 units/ml
penicillin, 100 μg/ml streptomycin, 100 ng/ml nerve
growth factor and 100 ng/ml human glial cell-line derived
neurotrophic factor. They were plated in slide glasses or
tissue culture dishes coated with 100 μg/ml poly-L-lysine
and 10 μg/ml laminin and maintained in an atmosphere
of 5% CO2/95% ambient air at 37°C for 72 hr. Following
incubation, the medium was removed, replaced with fresh
medium without horse serum, nerve growth factor and
human glial cell-line derived neurotrophic factor, and fur-
ther cultured at 37°C for an additional 24 hr.
DRG neurons were incubated with ATP for 5 min, and
KN-92, KN-93, A-317491 (Sigma, St Louis, MO, USA) or
cadmium (Sigma) was added to the neurons 10 min
before the application of ATP. After these treatments, the
medium was removed and the cultures were scraped into
RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% NP-40, 0.1% (w/v) SDS, 0.5% deoxycholate, protease
and phosphatase inhibitors cocktails) and centrifuged at
21,600 × g for 30 min at 4°C to remove cell debris. The
supernatant was transferred to a new tube, mixed with
Laemmli sample buffer and boiled at 95°C for 5 min.
Western blotting was carried out as described above. We
used anti-p-CaMKII antibody (1:1000, Promega) or anti-
CaMKII antibody (1:1000, Calbiochem) as additional pri-
mary antibodies.
Immunocytochemistry was performed as follows. Imme-
diately after treatment with ATP or BayK8644 (Sigma) for
5 min, cells were fixed with 3.7% formaldehyde. After
blocking, neurons were incubated with anti-p-cPLA2 anti-
body (1:200, Abcam) or anti-p-CaMKII antibody (1:500,
Promega) and then were incubated with anti-rabbit IgG-
conjugated Alexa Fluor 488 (1:1000, Molecular Probes)
followed by analysis with an LSM510 Imaging System
(Zeiss).
Immunoprecipitation
Immediately after treatment with ATP for 5 min, cultured
DRG neurons were rinsed once with PBS (-). RIPA buffer
was added to each plate and plates were incubated on ice
for 30 min. The cultured cells were scraped off and soni-
cated on ice three times for 5 s each. Protein samples were
centrifuged at 21,600 × g for 30 min at 4°C and then the
supernatants were transferred to a new tube, preabsorbed
with anti-rabbit IgG beads (eBioscience, San Diego, Cali-
fornia, USA) for 3 hr. The precleared protein extracts were
incubated with anti-p-cPLA2 antibody (1:50, Cell Signal-Molecular Pain 2009, 5:22 http://www.molecularpain.com/content/5/1/22
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ing) overnight at 4°C. Anti-rabbit IgG beads were subse-
quently added to the samples, and the mixture was further
incubated for 1hr at 4°C. The protein beads complexes
were washed four times with lysis buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% NP-40), and proteins were
eluted by boiling for 10 min in Laemmli buffer. Samples
were probed by western blotting using the corresponding
primary antibodies and Rabbit TrueBlot-horseradish per-
oxidase anti-rabbit IgG (1:1000, eBioscience) as a second-
ary antibody. The blots were detected using a
chemiluminescence method (ECL system).
Statistical analysis
All data are presented as means ± SEM. The statistical sig-
nificance of difference between values was determined by
Student's t test, Mann-Whitney U test or analysis of vari-
ance (ANOVA) with appropriate post hoc tests. A p value
less than 0.05 was considered to be statistically signifi-
cant.
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